Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204996 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01204996 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 53 participants.
The verdict
NCT01204996, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
Interventions
- DRUG CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
- DRUG CNTO888 + gemcitabine
- DRUG CNTO888 + Paclitaxel and carboplatin
- DRUG CNTO888 + docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204996
The ClinicalTrials.gov registry entry for NCT01204996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection is the first listed.
NCT01204996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204996 about?
NCT01204996 is a clinical study titled "A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors". The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
What is the current status of trial NCT01204996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2010-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01204996?
The interventions under investigation include: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection (DRUG), CNTO888 + gemcitabine (DRUG), CNTO888 + Paclitaxel and carboplatin (DRUG), CNTO888 + docetaxel (DRUG).
Who is sponsoring clinical trial NCT01204996?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.